Literature DB >> 27256076

Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate.

A J Zeder1,2, R Hilge3, S Schrader4, J R Bogner4, U Seybold4.   

Abstract

OBJECTIVES: The aim of this cross-sectional study was to evaluate the prevalence and risk factors of medium-grade proteinuria (100-500 mg/g creatinine) among HIV-positive adults.
METHODS: Spot urine samples of HIV-positive adults without known renal disease were analyzed quantitatively between January 2009 and February 2011. Demographic and medical data were collected. Multivariate regression models for different patterns of proteinuria were constructed.
RESULTS: Among 411 patients, 18 (4.4 %) presented albuminuria >300 mg/g creatinine and/or proteinuria >500 mg/g creatinine and were excluded from further analyses. Among the study population of 393 patients, 181 (46.1 %) had no significant proteinuria or albuminuria (<100 and <30 mg/g creatinine, respectively), 60 (15.3 %) had moderate albuminuria, while 152 (38.7 %) had proteinuria without albuminuria, suggesting tubular proteinuria. Independent predictors for medium-grade tubular proteinuria in multivariate analysis were exposure to tenofovir (DF), a CD4 nadir <500/µl, older age, and anti-HCV-antibodies. There was no association with classic renal risk factors like diabetes mellitus and arterial hypertension, or with estimated glomerular filtration rate (eGFR).
CONCLUSIONS: We detected significant proteinuria in 230 (56.0 %) of 411 HIV-positive patients. Among this group, 152 (66.1 %) had medium-grade proteinuria without albuminuria, which was significantly associated with exposure to tenofovir, older age, a lower CD4 nadir and Hepatitis C. Nephrologic or HIV treatment guidelines fail to detect most of these patients but rather identify patients with high cardiovascular risk. In the absence of an association with eGFR the role of medium-grade tubular proteinuria as a potential early marker of chronic kidney disease remains unclear. Prospective studies are needed.

Entities:  

Keywords:  Albuminuria; HIV; Proteinuria; Tenofovir; Tubular proteinuria

Mesh:

Substances:

Year:  2016        PMID: 27256076     DOI: 10.1007/s15010-016-0911-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  32 in total

1.  Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999.

Authors:  Richard M Selik; Robert H Byers; Mark S Dworkin
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-01       Impact factor: 3.731

2.  Low-grade proteinuria is highly prevalent in HIV-positive patients on antiretroviral treatment.

Authors:  Sophia Gravemann; Paul T Brinkkoetter; Jörg J Vehreschild; Bernd Franke; Kathrin Ehren; Elisabeth Bünemann; Henning Orbach; Verena Weiß; Martin Hellmich; Thomas Benzing; Gerd Fätkenheuer
Journal:  AIDS       Date:  2014-07-31       Impact factor: 4.177

3.  Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients.

Authors:  V Shahinian; S Rajaraman; M Borucki; J Grady; W M Hollander; T S Ahuja
Journal:  Am J Kidney Dis       Date:  2000-05       Impact factor: 8.860

Review 4.  Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence.

Authors:  Andrew M Hall; Bruce M Hendry; Dorothea Nitsch; John O Connolly
Journal:  Am J Kidney Dis       Date:  2011-03-23       Impact factor: 8.860

5.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

6.  Microalbuminuria in HIV disease.

Authors:  Colleen Hadigan; Elizabeth Edwards; Alice Rosenberg; Julia B Purdy; Estee Fleischman; Lilian Howard; JoAnn M Mican; Karmini Sampath; Akinbowale Oyalowo; Antoinette Johnson; Alexandra Adler; Catherine Rehm; Margo Smith; Leon Lai; Jeffrey B Kopp
Journal:  Am J Nephrol       Date:  2013-04-20       Impact factor: 3.754

7.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008.

Authors:  Nikolas Wada; Lisa P Jacobson; Mardge Cohen; Audrey French; John Phair; Alvaro Muñoz
Journal:  Am J Epidemiol       Date:  2013-01-03       Impact factor: 4.897

8.  Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate ≥ 60 ml/min per 1.73 m2.

Authors:  Jacques Reynes; Amandine Cournil; Hélène Peyriere; Christina Psomas; Elsa Guiller; Marlène Chatron; Jean-Paul Cristol; Stéphanie Badiou
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

Review 9.  Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure.

Authors:  Masaomi Nangaku
Journal:  Intern Med       Date:  2004-01       Impact factor: 1.271

10.  Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons.

Authors:  Andy I Choi; Yongmei Li; Steven G Deeks; Carl Grunfeld; Paul A Volberding; Michael G Shlipak
Journal:  Circulation       Date:  2010-01-25       Impact factor: 29.690

View more
  4 in total

1.  Proteinuria Is Associated With Increased Risk of Fragility Fracture in Men With or at Risk of HIV Infection.

Authors:  Anda Gonciulea; Ruibin Wang; Keri N Althoff; Michelle M Estrella; Deborah E Sellmeyer; Frank J Palella; Jordan E Lake; Lawrence A Kingsley; Todd T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2019-07-01       Impact factor: 3.731

2.  The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment.

Authors:  Anthony N Muiru; Erin Madden; Ani Chilingirian; Anna D Rubinsky; Rebecca Scherzer; Richard Moore; Celia P Corona Villalobos; Jose Manuel Monroy Trujillo; Chirag R Parikh; Chi-Yuan Hsu; Michael G Shlipak; Michelle M Estrella
Journal:  HIV Med       Date:  2021-12-12       Impact factor: 3.094

3.  Testicular ultrastructure and hormonal changes following administration of tenofovir disoproxil fumarate-loaded silver nanoparticle in type-2 diabetic rats.

Authors:  Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Oluwaseun Samuel Faborode; Ayobami Dare; Okikioluwa Stephen Aladeyelu; Roshila Moodley; Carmen Olivia Rennie; Edwin Coleridge Naidu; Onyemaechi Okpara Azu
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

Review 4.  Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI.

Authors:  S Höring; B Löffler; M W Pletz; S Rößler; S Weis; B T Schleenvoigt
Journal:  Infection       Date:  2018-06-30       Impact factor: 3.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.